Table 1 Strategies for designing and constructing nanomedicine against HMs
Clinical needs | Strategies | Nanomaterials or carriers |
|---|---|---|
Optimize the HSCT | I. Expansion of HSCs ex vivo | Nanoparticles, nanofibers, hydrogels |
II. Promote immune reconstitution | Bionic hydrogels | |
Boost immunotherapy | I. Improve antigen presentation | PLA NPs, hydrogels |
II. Improved CAR-T therapy | PGA polymer | |
Targeted drug delivery | I. Targeting TME | Bionic vesicles, living or dead cells |
II. Targeting cancer cells | Organic or inorganic nanoparticles | |
III. Targeting intracellular signals | Organic or inorganic nanoparticles | |
IV. Reverse multidrug resistance | Organic or inorganic nanoparticles |